Objective
Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals.
Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing.
To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.
The project will rely on 4 key components:
i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models;
(ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla);
(iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens;
(iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins).
We will
i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner;
ii) manufacture and perform initial human studies of the vaccine;
iii) identify additional antigens which might further increase the efficacy of the initial product.
Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- social sciences sociology demography mortality
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-HEALTH-2013-INNOVATION-2
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
OX1 2JD Oxford
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.